Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Accured Expenses: 2013-2024

Historic Change in Accured Expenses for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to -$10.2 million.

  • Seres Therapeutics' Change in Accured Expenses rose 106.96% to $633,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 147.60%. This contributed to the annual value of -$10.2 million for FY2024, which is 164.38% down from last year.
  • Per Seres Therapeutics' latest filing, its Change in Accured Expenses stood at -$10.2 million for FY2024, which was down 164.38% from $15.8 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Change in Accured Expenses ranged from a high of $43.0 million in FY2021 and a low of -$10.2 million during FY2024.
  • Its 3-year average for Change in Accured Expenses is $3.0 million, with a median of $3.3 million in 2022.
  • As far as peak fluctuations go, Seres Therapeutics' Change in Accured Expenses spiked by 1,040.94% in 2021, and later tumbled by 164.38% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Change in Accured Expenses stood at $3.8 million in 2020, then skyrocketed by 1,040.94% to $43.0 million in 2021, then slumped by 92.25% to $3.3 million in 2022, then soared by 374.76% to $15.8 million in 2023, then plummeted by 164.38% to -$10.2 million in 2024.